You are here: Home » Reuters » News
Business Standard

Novo Nordisk's $3.1 billion Ablynx bid rejected by Belgian biotech

Reuters  |  COPENHAGEN/BRUSSELS 

By Jacob Gronholt-Pedersen and Robert-Jan BartunekCOPENHAGEN/BRUSSELS (Reuters) - Denmark's Novo Nordisk, the world's biggest maker of insulin, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday as it seeks to bolster its treatments for rare blood disorders.Ablynx said it rejected Novo's latest takeover approach and analysts predict the Danish group, whose new chief executive is seeking growth by buying drugs developed by competitors, might face counterbidders and would need to raise its bid.The approach comes at a time of renewed interest by ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, January 08 2018. 18:19 IST
RECOMMENDED FOR YOU